Topline results reveal that VX-993 did not meet its primary endpoints, meaning Vertex will discontinue its development.

Here are seven reasons why Vertex is a no-brainer stock to buy on the dip. 1. The bad news wasn't as horrible as the sell-off ...

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators ...

Vertex Pharmaceuticals stock fell after quarterly earnings and revenue beat analysts’ expectations, overshadowed by bad news ...